Bayer has said it plans to withdraw its PI3K inhibitor Aliqopa from the US market as a treatment for follicular lymphoma (FL) after the drug failed a confirmatory trial, d
The FDA has granted Breakthrough Therapy Designation to Bayer’s PI3K inhibitor Aliqopa (copanlisib) for marginal zone lymphoma (MZL) patients who have received two prior therapies.
Bayer has gained FDA accelerated approval for its follicular lymphoma drug Aliqopa (copanlisib), giving it entry to the haemato-oncology market for the first time.
Just days after Telix priced a $200 million initial public offering (IPO) in the US, the Australian radiopharmaceutical specialist has abandoned the plan.